Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. - Concepedia

Concepedia

Publication | Closed Access

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

441

Citations

0

References

2000

Year

Richard I. Fisher, Steven A. Rosenberg, G. Fyfe

Abstract

With prolonged follow-up, treatment with high-dose recombinant IL-2 remains extremely effective for a subset of patients with metastatic renal cell carcinoma.